Five drops a day. That is the dose behind one of the more eye-catching supplement results in recent cognitive research. In a one-year randomized trial of people with mild cognitive impairment (MCI), those who added pomegranate seed oil (PSO) to a Mediterranean diet scored significantly better on memory and thinking tests than those who followed the diet alone.
The result is promising. It also comes with a big asterisk, covered below.
The study at a glance
The paper, published in the Journal of Alzheimer's Disease in 2024 by a team at the Greek Association of Alzheimer's Disease and Related Disorders and Aristotle University of Thessaloniki, is one of the first clinical trials of PSO in people with cognitive problems. The authors say they ran it because clinical data were lacking.
- Design: Randomized, two-arm trial
- Participants: 80 people diagnosed with MCI
- Intervention group (n=40): 5 drops of PSO per day plus the Mediterranean diet (MeDi)
- Control group (n=40): Mediterranean diet only, with no placebo oil
- Duration: One year
- Assessment: Extensive neuropsychological testing before and after the year
- Conflicts of interest: None declared by the authors
The headline numbers
After 12 months, the PSO group performed significantly better than the control group in three areas:
- Global cognition: p = 0.004
- Verbal episodic memory: p = 0.009
- Processing and executive functions: p < 0.001
Verbal episodic memory is the kind of recall you use to remember a conversation, a word list or a story. Processing and executive function covers mental speed, planning and attention control. These are the abilities that often start to slip in MCI.
One point of precision: the abstract reports that the PSO group did better than the control group. It does not give a detailed effect size, and it doesn't describe the oil as reversing MCI or preventing dementia. "Slowed decline" is a fair shorthand for the comparison between groups, but the paper's own claim is more modest. PSO was associated with better scores on these domains than diet alone.
Wait, what is PSO?
Pomegranate seed oil is not pomegranate juice, and it is not urolithin A.
- Pomegranate juice is water-based and rich in polyphenols such as ellagitannins and sugars.
- Urolithin A is a compound gut bacteria make from those polyphenols. It is sold as a separate supplement, often discussed in the context of mitochondrial health.
- Pomegranate seed oil is the fat extracted from the seeds. It is notable for a high content of unusual fatty acids, particularly punicic acid, a conjugated omega-5 fatty acid. The authors point to these fatty acids' antioxidant and anti-inflammatory properties as the rationale for testing the oil in neurodegeneration.
So the trial says nothing about juice or urolithin A. Swapping in a different pomegranate product is not the same intervention.
The big caveat: no placebo
The control group followed the Mediterranean diet and received no placebo oil. Everyone knew which group they were in. That makes this an open-label comparison, and it matters for three reasons:
- Expectation effects. People who know they are taking something may try harder, or feel more confident, on cognitive tests.
- Behavior differences. Taking a daily supplement can go along with other healthy habits that were not measured.
- Confidence in the size of the effect. Without blinding, we cannot be sure how much of the gap is the oil itself.
The results are statistically significant, but a placebo-controlled, double-blind trial would be needed to be confident in them. The study is also small, at 80 people, and was run at one center over one year.
What about biomarkers?
The same research group later published a follow-up (Biology, 2025) reporting blood biomarker improvements, including amyloid-beta and phosphorylated tau, in a subset of participants. That is intriguing because it suggests a possible biological signal. But it is a subset analysis from a small, open-label study, so treat it as hypothesis-generating rather than proof of a disease-modifying effect.
What this means for you
What was studied: 5 drops of PSO per day, taken alongside a Mediterranean diet, for one year. The abstract does not specify the product's volume per drop, the timing relative to meals or the brand beyond it being Greek PSO, so there is no evidence-based basis for fine-tuning timing. Anyone trying a product should follow its label and their clinician's advice rather than assuming equivalence with the trial material.
Who it may be relevant for:
- Adults with a diagnosis of MCI who are already working on lifestyle strategies and want to discuss adding a supplement with their doctor
- People interested in dietary approaches to dementia prevention, especially those already following a Mediterranean-style diet
Who should be cautious or skip it:
- Anyone without a clinical evaluation who is experiencing memory problems. Get assessed first; cognitive symptoms can have treatable causes.
- People who are pregnant or breastfeeding, have allergies, or take prescription medications, until they have spoken with a healthcare professional. The abstract describes PSO as a natural product that does not burden the body, but a trial of this size is not a comprehensive safety study.
- Anyone hoping to replace medical care or other proven measures. The authors describe PSO as a possible part of holistic approaches, not a standalone treatment.
Practical bottom line:
- The diet came first. Both groups followed the Mediterranean diet, so the oil is best seen as an add-on to the diet, not a substitute for it.
- Expect no miracles. The data show better test performance versus diet alone, not a cure.
- Wait for confirmation. A blinded, placebo-controlled trial with more participants would be the real test.
The takeaway
Five drops of pomegranate seed oil daily, on top of a Mediterranean diet, was associated with better global cognition, verbal episodic memory and executive function after a year in 80 people with MCI. It is an encouraging, low-effort signal from a research group with no declared conflicts, and it deserves a rigorous follow-up. But with no placebo and a small sample, it is a promising lead, not settled science.
